Safety of bevacizumab in the radiation treatment of recurrent malignant glioma: A pilot study
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioma
- Focus Adverse reactions
- 22 May 2017 Status changed from active, no longer recruiting to completed.
- 16 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 13 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.